Deerfield Management Company, L.P. (Series C) Dyne Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 435,653 shares of DYN stock, worth $5.93 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
435,653
Previous 435,653
-0.0%
Holding current value
$5.93 Million
Previous $15.6 Million
34.41%
% of portfolio
0.25%
Previous 0.29%
Shares
7 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$109 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$101 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$100 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$91.2 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$86.8 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $705M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...